HQL
Income statement / Annual
Last year (2023), Tekla Life Sciences Investors's total revenue was $23.52 M,
a decrease of 122.78% from the previous year.
In 2023, Tekla Life Sciences Investors's net income was $22.35 M.
See Tekla Life Sciences Investors’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
09/30/2023 |
09/30/2022 |
09/30/2021 |
09/30/2020 |
09/30/2019 |
09/30/2018 |
09/30/2017 |
09/30/2016 |
09/30/2015 |
09/30/2014 |
| Operating Revenue |
$23.52 M
|
-$103.25 M
|
$65.69 M
|
$124.08 M
|
-$69.34 M
|
$29.82 M
|
$69.81 M
|
$6.29 M
|
$1.32 M
|
$876,788.00
|
| Cost of Revenue |
$5.24 M |
$5.55 M |
$6.08 M |
$5.21 M |
$5.00 M |
$4.77 M |
$4.61 M |
$4.95 M |
$5.65 M |
$4.14 M |
| Gross Profit |
$18.28 M |
-$108.80 M |
$59.61 M |
$118.88 M |
-$74.35 M |
$25.05 M |
$65.20 M |
$1.34 M |
-$4.33 M |
-$3.26 M |
| Gross Profit Ratio |
0.78 |
1.05 |
0.91 |
0.96 |
1.07 |
0.84 |
0.93 |
0.21 |
-3.27 |
-3.72 |
| Research and Development
Expenses |
$0.00
|
-$3.28
|
$1.43
|
$3.15
|
-$1.84
|
$0.80
|
$1.46
|
-$1.89
|
$0.00
|
$0.00
|
| General & Administrative
Expenses |
$903,138.00
|
$1.08 M
|
$844,018.00
|
$751,317.00
|
$876,764.00
|
$880,756.00
|
$991,511.00
|
$5.23 M
|
$6.04 M
|
$4.64 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$903,138.00
|
$1.08 M
|
$844,018.00
|
$751,317.00
|
$876,764.00
|
$880,756.00
|
$991,511.00
|
-$1.89
|
$6.04 M
|
$4.64 M
|
| Other Expenses |
$22.62 M |
$275,967.00 |
$313,687.00 |
$278,662.00 |
$259,757.00 |
$466,641.00 |
$423,326.00 |
$20.74 M |
$143,440.00 |
$130,000.00 |
| Operating Expenses |
$23.52 M |
$1.35 M |
$1.16 M |
$1.03 M |
$1.14 M |
$1.16 M |
$1.26 M |
$13.35 M |
$39.18 M |
$88.39 M |
| Cost And Expenses |
$23.52 M |
$1.35 M |
$1.16 M |
$1.03 M |
$1.14 M |
$5.59 M |
$5.56 M |
$1.34 M |
$39.18 M |
$88.39 M |
| Interest Income |
$204,449.00 |
$50,092.00 |
$0.00 |
$164,800.00 |
$216,703.00 |
$90,706.00 |
$90,555.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$32.27 M |
$72.43 M |
$0.00 |
$45.22 M |
$93.03 M |
| Depreciation &
Amortization |
$0.00
|
$2.99 M
|
$4.14 M
|
$2.11 M
|
$2.88 M
|
$3.61 M
|
$3.88 M
|
$3.79 M
|
$4.72 M
|
$3.77 M
|
| EBITDA |
$22.35 M
|
-$104.61 M
|
$64.54 M
|
$123.06 M
|
-$70.47 M
|
$28.67 M
|
$68.56 M
|
$0.00
|
$0.00
|
$0.00
|
| EBITDA Ratio |
0.95 |
1.01 |
0.98 |
0.99 |
1.02 |
2.04 |
2.02 |
2.89 |
34.19 |
106.11 |
| Operating Income Ratio
|
-0.22
|
1.01
|
0.98
|
0.99
|
1.02
|
-0.12
|
-0.06
|
-0.6
|
-3.57
|
-4.29
|
| Total Other
Income/Expenses Net |
$27.60 M
|
-$101.61 M
|
$6.08 M
|
$5.21 M
|
-$67.60 M
|
$32.61 M
|
$72.74 M
|
-$8.12 M
|
$45.22 M
|
$93.03 M
|
| Income Before Tax |
$22.35 M |
-$104.60 M |
$64.53 M |
$123.05 M |
-$70.48 M |
$28.66 M |
$68.56 M |
-$11.91 M |
$40.50 M |
$89.27 M |
| Income Before Tax Ratio
|
0.95
|
1.01
|
0.98
|
0.99
|
1.02
|
0.96
|
0.98
|
-1.89
|
30.62
|
101.81
|
| Income Tax Expense |
$0.00 |
-$2.99 M |
-$4.15 M |
-$2.13 M |
-$2.88 M |
$1.00 |
$3.00 |
$26.32 M |
$45.22 M |
$93.03 M |
| Net Income |
$22.35 M |
-$104.60 M |
$64.53 M |
$123.05 M |
-$70.48 M |
$28.66 M |
$68.56 M |
-$11.91 M |
$40.50 M |
$89.27 M |
| Net Income Ratio |
0.95 |
1.01 |
0.98 |
0.99 |
1.02 |
0.96 |
0.98 |
-1.89 |
30.62 |
101.81 |
| EPS |
0.83 |
-4.07 |
2.66 |
5.16 |
-3.04 |
1.28 |
3.21 |
1 |
2.06 |
4.7 |
| EPS Diluted |
0.83 |
-4.07 |
2.66 |
5.16 |
-3.04 |
1.23 |
3.21 |
20740543 |
2.06 |
4.7 |
| Weighted Average Shares
Out |
$26.79 M
|
$25.68 M
|
$24.26 M
|
$23.85 M
|
$23.18 M
|
$22.41 M
|
$21.36 M
|
-$11.91 M
|
$19.69 M
|
$19.01 M
|
| Weighted Average Shares
Out Diluted |
$26.79 M
|
$25.68 M
|
$24.26 M
|
$23.85 M
|
$23.18 M
|
$23.30 M
|
$21.36 M
|
-$0.57
|
$19.69 M
|
$19.01 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
